Karrie International Holdings (1050) is organised into three major operating segments : (i) metal and plastic business; (ii) electronic manufacturing services business; and (iii) real estate business. Against the backdrop of the uncertainties concerning the China-US trade dispute and prevailing weak economy and trade, the core business of the Group remains stable and the real estate business has begun to reap its harvest. The Group has secured orders from existing customers for newgeneration server casings till 2022. The real estate business has made good progress and will provide shareholders with substantial earnings. (I do not hold the above stock)
Buy-in Price: $1.13, Target Price: $1.25, Cut Loss Price: $1.05
It is the largest workforce solutions provider in Greater China(the PRC, HK, Macau and Taiwan) region by revenue in 2018. It provides comprehensive workforce solutions and other HR services. Its largest stakeholder, ManpowerGroup Inc. is a New York Stock Exchange-listed world leader in workforce solutions and services. It operates more than 20 offices in over 130 cities in Greater China as of December 31, 2018. The company's 2019 interim revenue increased by 31.1% y.o.y. to RMB 1.441 billion, and the adjusted profit of continuing operations increased by 38.9% y.o.y. to RMB 56.1 million. The PRC's HR services industry has been growing rapidly from 2014 to 2018 at a CAGR of 20.9%, and is expected to grow at a CAGR of 19.9% due to the favorable government support and increasing demands from fast-growing emerging industries such as new retail, finance, ect. The PRC workforce solutions market expanded at a CAGR of 23.6% from 2014 to 2018, and is expected to grow at a CAGR of 21% until 2023.
Buy-in Price: $8.66, Target Price: $10.00, Cut Loss Price: $7.00
Sumitomo Corp (8053)
Established in 1919. Sumitomo group general trading company. Comprises six business fields, namely, Metal, Transportation & Construction Systems, Infrastructure, Media & Digital, Living Related & Real Estate, Mineral Resources, Energy, Chemical & Electronics. Developing and operating industrial parks in various South-East Asian countries.
For 1H (Apr-Sept) results of FY2020/3 announced on 1/11, revenue increased by 6.3% to 2636.6 billion yen compared to the same period the previous year, gross profit decreased by 1.0% to 446.9 billion yen, and net income decreased by 15.0% to 152.424 billion yen. Power generation and real estate businesses in Asia had performed well. However, profits declined in the final analysis due to sluggish coal and other resource businesses and the North American steel pipe business.
Company has revised its FY2020/3 forecast downwards during its results announcement. Current income is expected to decrease by 6.4% to 300.0 billion yen compared to the previous year (original plan 340.0 billion yen), and annual dividend per share to increase by 6.7% to 80 yen (original plan 90 yen). As production bases begin to shift from China to northern Vietnam as a result of the US-China trade war, we can look forward to positive impacts from Thang Long Industrial Park, the largest Japanese industrial park developed, sold and operated by the company. Dividend yield is also attracting attention.
Target Price : 1,800 yen
Buy Price : 1,620 yen
Cut-Loss : 1,480 yen
CR PHARMA (3320.HK) - Develop Segments Cooperation, Improve Business Synergy
Subsidiaries Maintained Growth in 3Q2019
For the nine months ended September 30, 2019, the operating revenue of CR Pharmaceutical Holdings, a wholly-owned subsidiary of the company, was RMB 135.022 billion (3Q2018: RMB 116.795 billion), representing an increase of 15.6% YoY; the net profit attributable to shareholders was RMB 2.465 billion (3Q2018: RMB 1.804 billion), a YoY increase of 36.6%.
For the nine months ended September 30, 2019, the revenue of Dong-E-E-Jiao, a subsidiary of the company, was RMB 2.83 billion (3Q2018: RMB 4.394 billion), a YoY decrease of 35.59%; the net profit was RMB 207 million (3Q2018: RMB 1.226 billion), a YoY decrease of 83.12%. The revenue of CR Sanjiu, a subsidiary of the company, was RMB 10.187 billion (3Q2018: RMB 9.444 billion), a YoY increase of 7.87%; the net profit was RMB 1.984 billion (3Q2018: RMB 1.137 billion), a YoY increase of 74.49%; based on preliminary assessment by the management of CR Sanjiu, the unaudited net profit attributable to the shareholders of CR Sanjiu for the year ended 31 December 2019 are estimated to be RMB 2.11 to 2.25 billion (FY2018: RMB 1.432 billion), an expected increase of 47.34% to 57.11% YoY; the significant increase in the net profit attributable to the shareholders is primarily attributable to the completion of disposal of its 82.89% equity interest in Shenzhen Sanjiu Hospital Co., Ltd. in January 2019, resulting in a net gain (after tax) of approximately RMB 680 million to CR Sanjiu. The revenue of CR Double-Crane, a subsidiary of the company, was RMB 7.407 billion (3Q2018: RMB 6.31 billion), a YoY increase of 17.39%; the net profit was RMB 930 million (3Q2018: RMB 864 million), a YoY increase of 7.64%. The revenue of Jiangzhong Pharmaceutical, a subsidiary of the company, was RMB 1.704 billion (3Q2018: RMB 1.292 billion), a YoY increase of 31.89%; the net profit was RMB 393 million (3Q2018: RMB 354 million), a YoY increase of 11.02%. In general, apart from Dong-E-E-Jiao, the performance of the company's subsidiaries has maintained steady growth, and with the gradual progress of Dong-E-E-Jiao, we are still optimistic about the company's performance as the industry leader in the future.
Continue to Increase and Optimize Product portfolio in the Pharmaceutical Sector
Recently, the company pointed out that it will use the channel advantage in the pharmaceutical sector to continuously increase and optimize its product portfolio in "CICC Forum 2019". The manufacturing business of the company encompasses the research and development, manufacturing and sale of pharmaceutical products. The company manufactured more than 540 products in 1H2019, of which morethan 300 were included in NRDL. The products comprise chemical drugs, Chinese medicines and biopharmaceutical drugs as well as nutritional and healthcare products, covering a wide range of therapeutic areas including cardiovascular, alimentary tract and metabolism, large-volume IV infusion, pediatrics, respiratory system etc.. The company had approximately 200 R&D projects in the pipeline, including 45 projects in the pipeline on innovative drugs. In addition, on October 3, 2019, NIP292, an innovative drug developed by the China Pharmaceutical Research and Development Center directly under the company's research and development platform, was approved by the US Food and Drug Administration (FDA) clinical trial and conducted a phase I clinical trial in the United States. NIP292 is primary treatment of pulmonary fibrosis (IPF), it is a new small molecule drug with multiple functions such as anti-inflammatory, anti-fibrosis, dilation of blood vessels, and repair of vascular endothelial injury. In addition to IPF, NIP292 has great potential for the treatment of autoimmune diseases, other fibrotic diseases, and malignant tumors. On October 23, CR Sanjiu, a subsidiary of the company, and Japan's Takeda Consumer Health Co., Ltd. signed an ALINAMIN product cooperation agreement in Beijing. CR Sanjiu will be responsible for the commercialization and sales of ALINAMIN in the Chinese market, and the two sides will also reach a consensus on other product portfolios and cross-border e-commerce business in the future. The company continues to improve R&D capability, enrich pipeline and access to products, and forge advantages of brand clustering, which is believed to benefit future development.
Market Share of the Circulation Sector is Expected to Further Increase
As at the end of 1H2019, distribution network of the company covered 28 provinces, reached 141 cities in total, serving over 100,000 downstream customers, including 6,862 Class II & III hospitals, and 53,640 primary medical institutions competitiveness in the Eastern China. The company continuously enhanced efficiency of the integrated and modernized intelligent logistics system, as at the end of 1H2019, the company operated 185 logistics centers in total. The company enhanced capability in providing value-added services to downstream customers, provided Hospital Logistic Intelligence (HLI) services to over 300 hospitals, and commenced Network Hospital Logistics Intelligence (NHLI) projects. In 1H2019, the company operated 842 retail pharmacies, of which 150 are DTP pharmacies covering 76 cities nationwide. The company continues to deepen the layout of pharmaceutical circulation sector, and enhances strength of the company through endogenous expansion and outreach acquisition, its market share is expected to further increase.
Maintain "BUY" Rating
We maintain the expected EPS of HKD 0.75/0.83/0.90. The target price was HKD 11.22, corresponding to FY19/FY20/FY21 14.95x/13.51x/12.48x PE, which was +66.51% higher than the current price (HKD 6.74 as of November 22, 2019), maintaining a ¡§BUY¡¨ rating.
Industry policy risk; M&A fails expectations.
Click Here for PDF format...
|Recommendation on 27-11-2019|
|Price on Recommendation Date||$ 6.740|
|Suggested purchase price||N/A|
|Target Price||$ 11.220|
| H share
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.
If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.
Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.